Rocket Pharmaceuticals revises RP‑A501 Phase II protocol and outlines pivotal trial plan
Rocket Pharmaceuticals announced a modified Phase II protocol for its RP‑A501 gene therapy after safety events in earlier cohorts. The new regimen removes the C3 inhibitor, lowers the dose to 3.8 × 10¹³ genome copies per kilogram, and adds extra rituximab dosing. The company plans a 12‑patient, male‑only pivotal trial targeting at least seven responders and expects dosing to finish by mid‑2027 with results in mid‑2028.
Why it matters
The company estimates the U.S. Danon disease market could generate more than $1 billion in peak annual revenue if the trial succeeds, so the protocol change directly impacts the commercial upside (the company estimates). An analyst quoted in one source says the stock could rise sharply on positive trial data.
Key facts
- 1Rocket removed the C3 inhibitor, reduced the dose to 3.8 × 10¹³ genome copies per kilogram, and increased rituximab from two to three doses. finance.yahoo.com
- 2Three patients have received the recalibrated dose as of the September 4 2026 data cutoff with no severe adverse events. finance.yahoo.com
- 3The pivotal Phase II trial will enroll 12 male patients and requires at least seven to meet both myocardial LAMP2 expression (≥ Grade 1) and a ≥ 10 % reduction in left ventricular mass index at 12 months. finance.yahoo.com
- 4Rocket expects to complete dosing by mid‑2027 and to have topline results by mid‑2028. finance.yahoo.com
- 5The company estimates the U.S. Danon disease population at approximately 10,000‑11,000 people, including about 4,000 males. finance.yahoo.com
- 6Rocket projects the initial indication could support more than $1 billion in global peak annual revenue. finance.yahoo.com
Summary written by AlphAI from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.